Imaging Multimodalities for Dissecting Alzheimer’s Disease: Advanced Technologies of Positron Emission Tomography and Fluorescence Imaging

Masafumi Shimojo, Makoto Higuchi, Tetsuya Suhara and Naruhiko Sahara *

Molecular Neuroimaging Program, Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, Japan

The rapid progress in advanced imaging technologies has expanded our toolbox for monitoring a variety of biological aspects in living subjects including human. In vivo radiological imaging using small chemical tracers, such as with positron emission tomography, represents an especially vital breakthrough in the efforts to improve our understanding of the complicated cascade of neurodegenerative disorders including Alzheimer’s disease (AD), and it has provided the most reliable visible biomarkers for enabling clinical diagnosis. At the same time, in combination with genetically modified animal model systems, the most recent innovation of fluorescence imaging is helping establish diverse applications in basic neuroscience research, from single-molecule analysis to animal behavior manipulation, suggesting the potential utility of fluorescence technology for dissecting the detailed molecular-based consequence of AD pathophysiology. In this review, our primary focus is on a current update of PET radiotracers and fluorescence indicators beneficial for understanding the AD cascade, and discussion of the utility and pitfalls of those imaging modalities for future translational research applications. We will also highlight current cutting-edge genetic approaches and discuss how to integrate individual technologies for further potential innovations.

Keywords: Alzheimer’s disease, biomarkers, multimodality, PET, fluorescence

INTRODUCTION

Progressive neuronal loss and dysfunction in specific brain circuits are common neurological features of neurodegenerative disorders. The fundamental mechanism of neurodegenerative onset is still largely unknown, but accumulating evidence has indicated that deposition of filamentous and/or soluble oligomeric aggregates of specific proteins with significant neurotoxicity generally serves as the initial trigger for the sequential cascade of disease-related pathophysiology. In brain of Alzheimer’s disease (AD) patients, senile plaques (SPs), and neurofibrillary tangles (NFTs) have been defined as two major pathological hallmarks, suggesting that the formation process of the resulting abnormal lesions is tightly linked to the pathogenic mechanism of AD. SPs are extracellular deposits composed of hydrophobic 38–49 amino acid peptides termed amyloid β (Aβ) and, since the discovery of the in vitro neuronal toxicity of aggregated Aβ species, numerous studies have indicated that brain accumulation of Aβ aggregates is a major causative risk factor for AD.
pathogenesis (Selkoe, 1991, 2001; Hardy and Selkoe, 2002). This “amyloid cascade hypothesis” is also strongly supported by the fact that Aβ metabolism is genetically linked to the familial AD causative genes β-amyloid precursor protein (APP) and Presenilins (PSs), adding major impetus to diverse therapeutic attempts to attenuate brain Aβ abnormality over the last two decades. However, in spite of these various advances in knowledge, no therapeutic approaches targeting Aβ have as yet successfully survived a Phase III trial (Huang and Mucke, 2012). This situation has now brought us to a turning point, as we need to re-evaluate our understanding of the consequences of AD pathophysiology and to carefully consider the direction of future therapeutic approaches so as to finally gain advantage over these complicated neurological disorders.

NFTs are composed of intra-neuronal and glial inclusions of hyperphosphorylated microtubule-associated protein Tau (MAPT), and they are widely observed in diverse tauopathies including progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD), suggesting their importance for general neurodegenerative abnormalities (reviewed in Lee et al., 2001). In the pathological course of AD, NFTs begin to appear in the entorhinal cortex and then spatially spread through a wide range of brain areas including the hippocampus, limbic system, and neocortex (Braak and Braak, 1991; Braak et al., 2011). The severity of NFT lesions is well-correlated with synaptic dystrophy and neuronal loss, followed by brain atrophy, and test results of cognitive and memory impairment also revealed correlation with brain accumulation of tau (Arrigada et al., 1992). Importantly, pathological mutations in the genetic locus of Tau gene have been identified in the family of frontotemporal dementia with Parkinsonism linked to MAPT on chromosome-17 (FTDP-17-MAPT) (Hutton et al., 1998; Poorkaj et al., 1998; Spillantini et al., 1998). Furthermore, recent studies have demonstrated that transgenic mouse models overexpressing human Tau transgene harboring pathogenic FTDP-17-MAPT mutations exhibit robust NFTs formation followed by neuronal loss and memory impairment (reviewed in Sahara et al., 2011). These findings suggest that abnormal aggregation and/or physiological malfunction of Tau protein has more potential significance for neurodegeneration, and indicate that the severity of tau pathology is also a potent biomarker for the early clinical diagnosis of AD.

As proposed in Braak's model, the pathological severities of SPs and NFTs in post-mortem AD brains can be categorized into progressive stages (stages A-C for SPs and I-VI for NFTs), providing fundamental criteria for a definitive diagnosis of AD (Braak and Braak, 1991, 1997). Hopeful attempts by AD researchers to establish visible biomarkers for tracing the real time course of Aβ and tau lesions in brain of living patients have followed a long, sometimes frustrating journey, as so far, histological findings at autopsy have usually suffered from technical limitations during the post-mortem procedure. In this regard, an in vivo imaging approach is particularly important for assessing the consequence of clinical symptoms and spatial dynamics of pathological lesions simultaneously. For this purpose, non-invasive neuroimaging techniques represented by positron emission tomography (PET) and magnetic resonance imaging (MRI) have a major significance, as they allow us to monitor both functional and structural circumstances in brain of AD patients (Mori et al., 2012; Jack and Holtzman, 2013). Aβ PET radiotracers have been developed and approved for clinical use, and they have added in shedding more light on the process of the early detection of AD (Yang et al., 2012). More recently, several laboratories including our group demonstrated the potential utility of tau-specific PET radiotracers to validate the spatiotemporal kinetics of the pathological stage of NFTs (reviewed in Ariza et al., 2015; Vilemagne et al., 2015). These consistent advances of radiological imaging technologies are really just a beginning stage, and further accumulations of new insights and important knowledge for constructing biomedical databases will be required for future translational research. It is important to realize that there is still a lot of room to manipulate and improve the capability of PET radiotracers in terms of binding specificity and chemical properties that can critically improve the diagnostic interpretation of PET neuroimaging. To visualize the brain status of AD more precisely, complimentary imaging approaches will be essential for assessing the detailed kinetics and fast dynamics of target molecules. Fluorescence-based imaging has great potential as a key technology to satisfy this aim. Although the utility of fluorescence is still restricted to animal models at this time, the major advantages of the fluorescence system are a variety of applications based on a wide range of probe design strategies including molecular genetics for dissecting the detailed molecular pathophysiology of neurodegenerative diseases. In this review, we will specifically introduce current imaging multimodalities beneficial for understanding the AD cascade and discuss how to integrate the respective modalities to the view of providing significant advances toward future translational research.

PET IMAGING FOR DIAGNOSIS OF ALZHEIMER’S DISEASE

General Usage for Brain PET Imaging
Radiological techniques supply a variety of applications for in vivo brain imaging, becoming a most effective approach in terms of the clinical diagnosis of neurological disorders. PET technology is especially adept at monitoring the behavior of neuronal molecules in living subjects including rodent, monkey, and human. Although the spatial resolution obtained by MRI, which is superior for morphometric analysis, is much higher than that of PET imaging, the performance of PET is greatest in the quantification of the kinetics of neuronal receptor molecules and chemical probe interaction in intact brain. In principle, chemical probes are labeled by positron emitting radionucleids such as $^{11}$C and $^{18}$F, and PET scan identifies the spatial location of these probes as radiotracers with high detection sensitivity and superior quantitative dynamic range (Piel et al., 2014). Therefore, we can directly obtain a densitometric 3D map of the accumulation level of radiotracers binding to targets. A number of small chemical compounds with high affinity to target molecules can be screened as potential
candidates of PET radiotracers without disrupting their parental structure and physicochemical properties. Only a small amount of radiation emitted from the tracer can be enough to allow detection, without any diffusion, and relatively fast decay of the radioisotope \( (t_{1/2} \approx 20 \text{ min for } ^{11}\text{C}, \sim 110 \text{ min for } ^{18}\text{F}) \) minimizes the radiation risk for patients (Piel et al., 2014). Furthermore, PET scan also provides important information about the detailed disposition and tissue circulation of the radiotracers themselves in brain, facilitating the design and synthesis of effective chemical derivatives that can successfully pass through the blood brain barrier (BBB) and penetrate brain tissue without obvious neurotoxicity (Piel et al., 2014). This basic feature of PET imaging makes this technology ideal for clinical use, and it also provides various potential utilities for scientific research.

**PET Tracers for Detecting Aβ and Tau Pathologies**

Since the initial discovery of the β-sheet enriched common structure in the aggregates of Aβ and tau, various β-sheet binding dyes such as congo-red and thioflavin have been isolated as candidate compounds for PET imaging, and their use for visualizing SPs and NFTs in animal models and human subjects has been attempted. Representative and currently available Aβ and tau PET tracers are listed in Table 1. The earliest PET studies identified the capability of \(^{18}\text{F} \)FDDNP, a fluorine-modified derivative of the lipophilic compound DDNP, as Aβ PET tracer (Barrio et al., 1999; Small et al., 2006). However, this tracer has not become widely used for *in vivo* imaging because it demonstrates a relatively low signal-to-noise ratio, and it also recognizes NFTs, which makes interpretation difficult (Shoghi-Jadid et al., 2002; Thompson et al., 2009; Smid et al., 2013). A superior Aβ-specific PET tracer termed \(^{11}\text{C} \)Pittsburgh Compound-B (\(^{11}\text{C} \)PiB) was screened as a derivative of thioflavin T, and it is now the most widely characterized radio ligand with improved sensitivity and high specificity against Aβ aggregate (Klunk et al., 2004). A \(^{18}\text{F} \)labeled analog of PiB, termed \(^{18}\text{F} \)FLPIB (Flutemetamol; Vizamyl, GE Healthcare), was developed for diagnostic application and was approved by the US Food and Drug Administration (Yang et al., 2012). In parallel, other Aβ PET tracers, \(^{18}\text{F} \)AV-45 (florbetapir; Amyvid, Eli Lilly) and \(^{18}\text{F} \)AV-1 (florbetaben; Neuraceq, Piramal Imaging), have also been independently engineered from diaryl alkenes and are currently available for clinical diagnosis (Herholz and Ebmeier, 2011; Vallabhajosula, 2011). For the purpose of standardizing the difference of these Aβ PET tracers, several groups have investigated direct comparison of PET imaging data obtained by sequential scanning using several tracers in the same cohort (Vandenbergh et al., 2010; Wolk et al., 2012; Landau et al., 2013, 2014). As for the cortical retention ratio of \(^{11}\text{C} \)PiB, both \(^{18}\text{F} \)F′-FPiB and \(^{18}\text{F} \)AV-45 demonstrate a highly significant ability to discriminate between control subjects and AD patients, with a high linear correlation to the data obtained by \(^{11}\text{C} \)PiB. However, it has been pointed that the retention level in white matter varies among the tracers, which makes it more challenging to precisely measure the cortical retention ratio to the reference brain region such as the brain stem, which contains a large amount of white matter (Landau et al., 2014). Hence, it would still be a worthwhile investment to improve and characterize the capability of Aβ PET tracers (Kudo et al., 2007; Yousefi et al., 2011; Cserenyi et al., 2012). The development race of Tau PET tracers is just heating up (reviewed in Ariza et al., 2015; Villemagne et al., 2015). Three lines of chemical probes have been independently screened and characterized for their potential clinical utility (Table 1). \(^{18}\text{F} \)THK523 was originally engineered as a derivative of quinoline, and it demonstrates high affinity and selectivity for tau aggregates in *in vitro* assay (Fodero-Tavoletti et al., 2011). Although human PET imaging using \(^{18}\text{F} \)THK523 indicated its specificity not for Aβ but for NFTs, a relatively high background of this radiotracer in white matter was initially anticipated for its further clinical use (Fodero-Tavoletti et al., 2011; Harada et al., 2013). Improved novel radiotracers labeled \(^{18}\text{F} \)THK5105,

| Target | Radiotracer for PET imaging of SPs or NFTs | Approval for clinical use | References |
|---|---|---|---|
| Aβ/SPs | \(^{18}\text{F} \)FDDNP | | Barrio et al., 1999; Shoghi-Jadid et al., 2002; Small et al., 2006; Thompson et al., 2009; Smid et al., 2013 |
| Aβ/SPs | \(^{11}\text{C} \)PiB | Flutemetamol; Vizamyl, GE healthcare | Klunk et al., 2004 |
| Aβ/SPs | \(^{18}\text{F} \)F′-FPiB | Florbetapir; Amyvid, Eli Lilly | Yang et al., 2012 |
| Aβ/SPs | \(^{18}\text{F} \)AV-1 | Florbetaben; Neuraceq, Piramal Imaging | Rowe et al., 2008 |
| Aβ/SPs | \(^{18}\text{F} \)AV-45 | | Choi et al., 2009 |
| Tau/NFTs | \(^{18}\text{F} \)THK523 | | Fodero-Tavoletti et al., 2011; Harada et al., 2013 |
| Tau/NFTs | \(^{18}\text{F} \)THK5105 | | Okamura et al., 2014 |
| Tau/NFTs | \(^{18}\text{F} \)THK5117 | | Okamura et al., 2014 |
| Tau/NFTs | \(^{18}\text{F} \)THK5351 | | Villemagne et al., 2014 |
| Tau/NFTs | \(^{18}\text{F} \)T807 | | Xia et al., 2013 |
| Tau/NFTs | \(^{18}\text{F} \)T808 | | Zhang et al., 2012 |
| Tau/NFTs | \(^{11}\text{C} \)PBB3 | | Maruyama et al., 2013 |
and [18F]THK5117 and [18F]THK5351, 2-aryquinoline derivatives, were recently engineered by the same group and demonstrated superior affinity and specificity in in vitro assays, making these tracers promising candidates for tau PET imaging (Okamura et al., 2014; Tago et al., 2014; Villeremagne et al., 2014). [18F]T807 and [18F]T808, also screened as benzimidazole pyrimidine derivatives, demonstrated specific selectivity to tau aggregates with nano-molar affinity (Zhang et al., 2012; Xia et al., 2013). Human PET studies using these radiotracers revealed significant association between clinical severity and their cortical retention, and this observation was also followed by a good correlation with post-mortem pathological NFT lesions (Chien et al., 2013). [11C]PB3 was developed as a phenyl/pyridinyl-butadienyl-benzothiazoles/benzothiazolium (PBB) derivative that possesses superior affinity and specificity for NFTs, much higher than for SPs, by radioautography using brain sections from both rodent models and AD patients (Maruyama et al., 2013). [11C]PB3 PET analysis of AD patients and non-AD tauopathies revealed that the severity of tau accumulation correlates well with clinical scores and follows the pathological staging model proposed by Braak. Because of it being a relatively new topic, as well as the highly competitive nature of this research field, a side-by-side direct comparison of the capability of the respective tau PET tracers in the same individuals has not yet been achieved. However, recent studies based on in vitro binding assays indicate that those various tracers demonstrate preferential binding capability to distinctive tau pathologies observed in AD and non-AD, suggesting each tracer potentially recognizes the different structural status of tau aggregates (Maruyama et al., 2013; Marquie et al., 2015). Overall, current tau PET imaging is promising, and detailed characterization and improvement of independent radiotracers will provide better clinical insight and shed greater light on the detection of AD progression.

Non-Amyloid PET Imaging for Detecting Disease Progression

In addition to Aβ and Tau PET imaging, various disease-associated pathophysiology such as aberration of energy metabolism, glial inflammation, dysfunction of calcium homeostasis, and imbalanced neuronal activity can also be targeted as potential biomarkers of AD progression. The benefits of characterizing these additional biological parameters for AD diagnosis are the following: (i) accumulating a repertory of biomarkers will eventually contribute to establishing a PET biomarker database that will allow us to conduct more precise diagnoses and case-by-case categorizations with unbiased criteria by the combinations of several parameters; (ii) the signal-to-noise ratio of current amyloid PET imaging is still being developed and is not yet sufficient to detect early stages of pathological lesions; (iii) some of the biomarkers can be useful for the diagnosis of other neurodegenerative disorders as common pathophysiological abnormalities. [18F]fluorodeoxy glucose ([18F]FDG) PET scan has been conducted to identify glucose hypometabolism in AD patients, and it is generally selected as the initial choice for the clinical diagnosis of AD (McGeer et al., 1986; Mosconi, 2005). However, the difficulty in identifying a specific and precise time window of the AD status has been a matter of debate, as [18F]FDG hypometabolism reflects various mixture effects including less neuronal excitability and neuronal loss, which are widely observed in various neurodegenerative disorders (Jack and Holtzman, 2013). Brain inflammatory response with reactive gliosis is the other potential target for staging AD progression (Heppner et al., 2015). A considerable amount of evidence has indicated that activated reactive astrocytes contribute to clearing SPs in the early stage of AD. Since the inflammation is massively amplified by the paracrine neuroprotective response, it would be one of the key candidates as an early-stage biomarker that can detect subtle changes indicating pathological abnormality. In fact, using a tau transgenic mouse model, it was demonstrated that microglial activation proceeds to NFTs formation (Yoshiyama et al., 2007), suggesting its potential utility as a much earlier-stage diagnostic biomarker. This evidence supports the concept of the potential utility of several inflammation-related molecules for early clinical diagnosis. On the other hand, it has been debated whether inflammatory response represents both aspects of neuroprotective and neurodegenerative signals (Higuchi et al., 2010; Heneka et al., 2015; Heppner et al., 2015). Particularly, there is evidence that prolonged microglial activation accelerates the neurodegenerative process (Maeda et al., 2007; Ji et al., 2008), suggesting a potential difficulty for interpreting inflammatory parameters as early-stage biomarkers. In any case, it should be feasible to target a molecule that can segregate astrocytic and microglial activations. Based on this concept, TSPO (Translocator Protein 18kDa, also known as Peripheral Benzodiazepine Receptor; PBR) has been targeted for imaging neuroinflammation (reviewed in Jacobs et al., 2012). Since increased TSPO expression in activated microglia has been associated with a number of neurological diseases (reviewed in Venneti et al., 2006), several PET tracers for TSPO (e.g.; [11C](R)PK11195, [11C]PBR28, [11C]DAA1106, [11C]AC5216, and [18F]DPA-714) have been studied to visualize the microglial activation in animal models and AD patients (Jacobs et al., 2012; Mori et al., 2012; Golla et al., 2015). However, there are several limitations of current TSPO ligands such as selectivity to microglia and different affinity in polymorphisms (reviewed in Venneti et al., 2013; Turkheimer et al., 2015). Regardless, imaging neuroinflammation will offer one of diagnostic tools for neurological diseases.

Pitfalls of PET Imaging

PET imaging is an extremely powerful tool for the purpose of non-invasive clinical diagnosis. However, it is still not easy to install these imaging systems into a single laboratory; it would be a costly and space-consuming challenge to establish a special radiation control facility requiring a high level of expertise for the maintenance and manipulation of radioactive molecules. In addition, there are also technical limitations in regard to spatial and temporal resolution, and there is not yet a suitable approach for evaluating binding specificity and molecular dynamics of the tracer, pivotal criteria for reliable imaging interpretation. For instance, despite the development of newly screened radiotracer candidates based on considerable effort and time for synthesis
and radiolabeling, in vitro and ex vivo binding assays such as autoradiography under low magnification are recognized as so far being the sole method for verifying the capability of the tracer. An additional weakness of PET technique is the inability to obtain new biological insight into the structural and/or environmental status of target molecules, meaning that the solid radiation signal we monitor during PET scans completely lacks that kind of molecular-based information. Therefore, an ideal approach would be to evaluate the biological validity and capability of the tracer by complementary technologies side-by-side, and this would comprehensively enhance the developmental productivity by mutual complementary and synergistic effect of different technologies. In the next section, we will discuss the utility of fluorescence imaging in the effort to lessen the gap in PET imaging.

**FLUORESCENCE IMAGING TO DISSECT MOLECULAR PATHOPHYSIOLOGY**

**Utility of Fluorescence for In vivo Brain Imaging**

During the rapid evolution of optical microscope technologies over the last several decades, fluorescence imaging has become a powerful tool for current modern neuroscience (Giepmans et al., 2006; Wilt et al., 2009). A variety of microscope systems with combinations of many available fluorescence probes supply a wide range of applications including single molecular analysis, live cell imaging, and conventional histological analysis in animal brain. In particular, the recent availability of the multi-photon excitation technique has broken down the limitation of optical scattering in thick tissues and expanded the utility of fluorescence for in vivo brain imaging in animal models (reviewed in Svoboda and Yasuda, 2006). In this system, only target fluorophores in a restricted volume can be excited by simultaneous photon absorption using a long-wavelength pulse laser, allowing us to illuminate molecular dynamics up to a depth of ~1 mm. To conduct a long period of efficient excitation and detection (at least 1 month), setting of a chronic cranial window onto the bone of the skull is generally used (Tomita et al., 2005). Furthermore, current progress of fluorescence-based microendoscopy using optical fibers has enabled us to conduct cellular level imaging within the deep areas of brain tissue such as hippocampus and striatum in freely moving animals (reviewed in Mehta et al., 2004; Oh et al., 2013). In spite of mechanical inflexibility and physical invasiveness caused by surgical insertion of submillimeter-diameter fiber optic devices, it offers potential applications for longitudinal studies of disease progression (Barretto et al., 2011). At this stage, these approaches are specifically limited to usage in rodent models and is technically still far removed from any availability for human diagnosis. However, the combinatorial use of the AD mouse model with multi-color fluorescence probes should represent a beneficial approach for the monitoring of the progressive course of the AD cascade simultaneously, relying on fast temporal kinetics and high spatial resolution.

**In vivo Fluorescence Imaging for Detecting Aβ and Tau Pathologies**

As most of the β-sheet binding chemical compounds engineered for PET radiotracers possess their own fluorescence derived from a polycyclic aromatic hydrocarbon backbone structure, these small chemical compounds have ideal multimodalities for side-by-side in vivo imaging comparison by both fluorescence and PET techniques (Hawe et al., 2008). So far, studies focusing on the beneficial usage of in vivo fluorescence approaches have been published from only a few laboratories (Table 2). As pioneer studies, SPs in APP transgenic mouse, which demonstrates massive Aβ pathology, were first successfully visualized by the hydrophilic chemical compound Thioflavin S or by anti-Aβ antibody conjugated to fluorescein by two-photon microscopy (Bacskai et al., 2001; Christie et al., 2001). Since these reagents cannot penetrate BBB, the authors injected them directly into the imaging area of the brain surface, demonstrating that the size and morphology of SPs are rapidly cleared by immunization with Aβ peptide during the course of a few days (Bacskai et al., 2001). The relatively hydrophobic Congo-Red derivative Methoxy-X04 was next developed and used to visualize Aβ pathology in brain of APP transgenic mouse by intraperitoneal bolus administration (Klung et al., 2002). In addition, importantly, it was also verified that Pittsburgh Compound-B (PiB) successfully visualized SPs in mouse brain parenchyma by intravenous administration, opening a new possibility for the simultaneous characterization of a chemical tracer for both fluorescence and PET imaging (Bacskai et al., 2003). The advantage of these compounds is their ability to pass through BBB and therefore provide very important information on the kinetics and tissue distribution of Aβ pathology with great spatiotemporal resolution (~1 μm for spatial and ~sec for temporal). Although initial studies have suggested a relatively stable appearance of existing SPs over several months, more recent studies indicated that both SPs and cerebral amyloid angiopathy (CAA), the cerebrovascular Aβ deposition in arterial vessels, grow at a consistent rate (Robbins et al., 2006; Garcia-Alloza et al., 2007; Hefendehl et al., 2011). It has also been demonstrated that newly developed SPs grow rapidly for 24 h and dynamically change their morphology, suggesting that steady-state Aβ pathology undergoes flexible regulation by various environmental factors in living animal. Similar approaches to visualize tau pathology in Tau transgenic mouse model have also been used. By direct application of Thioflavin S, NFTs with neuronal loss in brain of rTg4510 tau transgenic mice were first evaluated by multi-photon microscopy (Spire-Jones et al., 2008). X-34, a Congo-Red derivative, and PBB3 were next independently developed by different groups and used for successful visualization of NFTs with great spatiotemporal resolution by intravenous injection in living mouse models (de Calignon et al., 2010; Maruyama et al., 2013). Although the detailed in vivo time course of NFTs formation has not yet been well-characterized, these studies promise the dual utility of the compounds for both radiological and fluorescence in vivo imaging applications. Importantly, both local abnormalities of Aβ and Tau pathology can be detected by multi-photon excitation at a very early stage, indicating that the fluorescence approach
TABLE 2 | Reference list for in vivo fluorescence imaging in living mouse model.

| Mouse model | Reagents and application for in vivo visualization of SPs or NFTs | Fluorescence reporters for in vivo visualization of AD pathophysiology | References |
|-------------|-------------------------------------------------|-------------------------------------------------|-------------|
| PDAPP (APP V717F) | Thioflavin S, anti-Ab w/Fluorescein (intracerebral injection) | — | Bacskaï et al., 2001 |
| Tg2576 (APPsw) | Thioflavin S, anti-Ab (10D5) conjugated Cy3 (intracerebral injection) | — | Christie et al., 2001 |
| PS-APP (PS1M146L vs. Tg2576) | Methoxy-X04 (i.p.) | — | Künk et al., 2002 |
| PDAPP/Tg2576PS-APP | Thioflavin T, Thioflavin S, PIB (i.v.) | — | Bacskaï et al., 2003 |
| Tg2576 | Methoxy-X04 (i.p.) | — | Robbins et al., 2006 |
| PS1dEx9/APPsw | curcumin (i.v.) | — | Garcia-Alloza et al., 2007 |
| PS1L166P/APPsw | Methoxy-X04 (i.p.) | — | — |
| 3xTg-ADAPPdutch/iowaTg2576 | — | flou-4 AM | Hefendehl et al., 2011 |
| PS1dEx9/APPsw | Methoxy-X04 (i.p.) | YC3.60 camereon (AAV, intracerebral injection) | Takano et al., 2007 |
| PS45(APP5348A)/APP23(sw) | Thioflavin S (intracerebral injection) | Oregon green BAPTA | Busche et al., 2008 |
| PS1dEx9/APPsw | Methoxy-X04 (i.p.) | Oregon green BAPTA | Kuchibhotla et al., 2009 |
| PS45/APP23 | Thioflavin S (intracerebral injection) | Fluo-8 AM | Busche et al., 2012 |
| PS1dEx9/APPsw | Methoxy-X04 (i.p.) | CaMKII 5′UTR-EGFP/Venus-3′UTR (AAV, intracerebral injection) | Meyer-Luehmann et al., 2009 |
| PS1dEx9/APPsw | Methoxy-X04 (i.p.) | Crossbreeding to Arc/dVenus mice | Rudinsky et al., 2012 |
| Tg2576 | Methoxy-X04 (i.p.) | Crossbreeding to B6C2-YFP mice | Meyer-Luehmann et al., 2008 |
| PDAPP | Methoxy-X04 (i.p.) | Crossbreeding to Ox3CR1/GFP mice | — |
| rTg4510 (Tau P301L) | Thioflavin S (intracerebral injection) | FLICA (intracerebral injection) | Koenigskecht-Talbou et al., 2008 |
| rTg4510 (Tau P301L) | Thioflavin S (intracerebral injection) X-34 (i.v.) | FLICA (intracerebral injection) | Spires-Jones et al., 2008 |
| PS19 (Tau P301S) | PBB3 (i.p., l.v.) | — | de Calignon et al., 2010 |
| rTg4510 (Tau P301L) | Thioflavin S (intracerebral injection) | YC3.60 camereon (AAV, intracerebral injection) | Maruyama et al., 2013 |
| rTg4510 (Tau P301L) | Thioflavin S (intracerebral injection) | YC3.60 camereon (AAV, intracerebral injection) | Kuchibhotla et al., 2014 |

has a greater advantage for identifying beneficial molecular clues linking early pathological change in AD model animals.

Utility of Fluorescence Biosensors of AD Pathophysiology

Recently, unique functional fluorescence biosensors to monitor biophysical properties were developed for dissecting the detailed physiological status of animal brain. Since Green fluorescent protein (GFP) was discovered from jellyfish *Aequorea victoria* by Shimomura et al., many unique native fluorescent proteins emitting diverse colors have been isolated from multiple marine organisms (Shimomura et al., 1962). The improved fluorescent proteins in terms of wavelength, brightness, photostability, and less oligomeric property were successfully engineered by random mutagenesis analysis, and the fluorescent protein color palette has been extensively matured from blue to a near-infrared spectrum (Giepmans et al., 2006). Engineered fluorescent proteins with enhanced unique original properties (e.g., photo activation/conversion, environment sensitivity, etc. …) have also been created during this process, opening a new window to the utility of fluorescent proteins as molecular biosensors generally termed “genetically encoded fluorescence indicators” (GEFIs) to monitor a wide variety of biological parameters including calcium, voltage, ATP, cAMP, glutamate, and kinase activities (Knopfel, 2012; Miyawaki and Niino, 2015). In addition, approaches to the use of virus-mediated gene delivery or conventional animal genetics with specific promoter-dependent regulation allow us to manipulate specific subpopulations of neurons or glial cells, and GEFIs are certain to become a powerful and broadly used tool for dissecting the molecular pathophysiology of neurodegenerative disorders.

With the combination of fluorescence reporters and biosensors, attempts have been made to illuminate the more complicated AD-related pathophysiology by multi-photon excitation techniques (Table 2). Abnormal dendritic curvature and spine loss associated with SPs in brain of APP transgenic mouse were first illuminated in living neurons expressing GFP by either Adeno associated virus (AAV)-mediated manipulation or by crossbreeding with fluorescence reporter mouse (Spires et al., 2005). Using AAV-mediated overexpression of YC3.6 calcium sensor proteins, Aβ pathology-related aberrant overloading of neuronal calcium in the somatosensory cortex was then
detected with great temporal resolution (Kuchibhotla et al., 2008). Interestingly, local administration of Oregon-Green BAPTA (OGB), a small-molecule calcium dye, also revealed hyperactivity in neurons and disrupted synchronous calcium oscillation in the astrocyte network associated with Aβ pathology (Busche et al., 2008; Kuchibhotla et al., 2009). In addition, inhibition of Ca2+/calmodulin-dependent protein phosphatase 2B (Calcineurin) attenuated the calcium dysregulation and structural abnormality of neurites. These findings suggest that dysfunction of calcium homeostasis is one of the key environmental parameters related to amyloid pathology. In addition to these observations, cross-breeding of APP transgenic mice with Cx3CR1 mice, which specifically express GFP in microglial cells, identified robust microglial activation associated with Aβ pathology (Meyer-Luehmann et al., 2008). Importantly, this immune response has been constantly observed during both the development of SPs and anti-Aβ immunization, suggesting that inflammation plays an essential role in the regulation of the dynamics of Aβ pathology (Koenigsknecht-Talboo et al., 2008). As an additional unique fluorescence reporter, transgenic mouse expressing destabilized Venus under control of immediate early gene Arc promoter was generated to identify disrupted orchestrated neuronal network activity in an APP transgenic mouse model (Rudinskiy et al., 2012). Taken together, these studies strongly indicate the power of the fluorescence system in combination with the current genetics approaches to provide major insights into the AD pathophysiology. Using the fluorescence indicator of caspase activation (FLICA), it was also demonstrated that the majority of caspase-positive neurons contain NFTs in brain of rTg4510 tau transgenic mouse (Spires-Jones et al., 2008). Interestingly, infrequent NFT-negative neurons demonstrated rapid suppression of caspase activity followed by NFTs formation within 1 day (de Calignon et al., 2010). This indicates that NFTs formation potentially has a neuroprotective role against caspase-mediated neuronal apoptosis. The other surprising observation was that rTg4510 tau transgenic mouse demonstrated normal calcium dynamics despite massive synaptic loss in both sensory and visual cortex, suggesting that tau-related synaptic abnormality was induced by a calcium-independent mechanism (Kopeikina et al., 2013; Kuchibhotla et al., 2014). Dissection of the brain status of tau transgenic mouse model by in vivo fluorescence imaging is still at a developmental stage, and therefore additional studies with fluorescence reporter can be expected to further expand the future potential and contribution of the tau-related pathophysiology of AD.

Limitations of Fluorescence Imaging

As we summarize in this section, fluorescence-based optic imaging has become an attractive approach to simultaneously monitor the interaction between target molecules and disease-related pathophysiology with high spatiotemporal kinetics, and to offer solid molecular-based insight for dissecting the in vivo mechanism underlying the progression of the neurodegenerative process in AD model animals. It also offers a relatively simple and inexpensive system that can be relatively easy to install into laboratory space, and potentially provide powerful biomedical applications such as in vivo high-throughput drug screening. However, considering future in vivo applications, there are still many technical challenges and space that will require solutions. First, the issue of optical diffusion tissue in vivo still strongly restricts the visualization of fluorophore in only the surface area even in mouse brain (reviewed in Svoboda and Yasuda, 2006). Second, the potential invasiveness and toxicity caused by both the surgery process and local genetic manipulation limit the usage of these techniques in animals, although not in human (reviewed in Hillman, 2007). Third, it is also important to note that overexpression of fluorescent reporter proteins potentially has undesirable photostability, toxicity, and mislocalization (reviewed in Shaner et al., 2005). Based on an understanding of these advantages and disadvantages, we will then consider how to integrate each of the imaging modalities in the future as described in the last section.

Perspectives for Future Imaging Multimodality

PET Imaging for Early Detection of AD Pathology

The current successful establishment of Aβ and tau PET radiotracers in combination with the available biomarkers promises the availability of PET imaging for the clinical diagnosis of AD. The next challenge for future PET neuroimaging is the design of more advanced chemical probes that specifically recognize the distinct conformational and/or modification status of aggregates. In fact, it is known that PiB efficiently detects SPs in AD brain but not in mouse brain, suggesting that a modification process in different biological species can influence the in vivo binding capability of the tracer (Klungk et al., 2005). Recent studies suggest that not filamentous but soluble oligomeric aggregates of Aβ and tau are toxic species during the pathological course of AD (Cheng et al., 2013). In particular, tau protein undergoes multiple post-translational modifications such as phosphorylation, nitration, or truncation, which are predicted to associate with the pathogenic mechanism(s) of AD (Marcus and Schachter, 2011). Using in vitro aggregation assay, several groups have successfully identified unique chemical compounds that preferentially bind to intermediate aggregated species of Aβ and tau (Wischik et al., 1996; Bolognesi et al., 2010; Smith et al., 2010; Carrasco-Gallardo et al., 2012; Jameson and Dzyuba, 2013; Teoh et al., 2015). More recently, pentameric formyl thiophene acetic acid (pFTAA) was screened to successfully visualize the conformation specific status of tau aggregates in living dorsal root ganglion neurons isolated from tau transgenic mouse model (Brelstaff et al., 2015). Therefore, some chemical compounds that potentially have specific binding affinity to toxic oligomer or modified species of Aβ and tau might be more suitable tracers for the early detection of AD pathology. Various intermediates of tau aggregates have been isolated during the pathological course of NFTs formation, and it has been highly debated whether soluble oligomeric aggregates of tau are toxic species (Makrides et al., 2003; Maeda et al., 2006; Sahara et al., 2007; Peterson et al., 2008; Lasagna-Reeves et al., 2010; Bader et al., 2011; Patterson et al., 2011). It has also been hypothesized that the formation process of intracellular tau inclusion potentially has a trophic role against...
tau toxicity (Spires-Jones et al., 2011; Cowan and Mudher, 2013). In this regard, to segregate the early pathological tau species that are toxic vs. those that are more neuroprotective would be a more challenging, but also a more attractive investment for advanced preclinical diagnosis. A fluorescence-based imaging approach will have a great advantage in addressing this fundamental issue. Current elegant studies have also demonstrated a cell-based fluorescence system that can detect the very early stage of tau aggregates isolated from juvenile tau transgenic mouse brain by fluorescence resonance energy transfer (FRET), pointing out its potential complementary application as a more physiological drug screening system (Holmes et al., 2014). Taken together, it is clearly important to expand multimodal imaging approaches to characterize the basic capability of chemical compounds, and this will eventually improve the screening efficiency and open attractive directions for more sophisticated molecular diagnoses with appropriate data interpretation.

Genetic Manipulation of Animal Models

To follow this multimodal approach, a key component would be advancing technical innovation for genetic manipulation. Many transgenic/knock-in mouse models overexpressing mutant APP, PSs, and/or Tau have been established during the last two decades, and a tremendous amount of fundamental knowledge about the AD cascade has been acquired. However, these classical genetic systems still have many limitations, as follows. First, it is quite difficult to reproduce the spatiotemporal dynamics of the AD pathological progression in these classical models because transgene overexpression is controlled by specific promoter activity. Second, it is still expensive and time-consuming to generate mouse lines, and technical innovation to improve productivity will be required. Third, rodent models may in fact represent the ultimate limitation to the reproduction of the human brain circumstances because of the species barrier. As an advanced mouse model, a drug inducible Cre-loxP system, or a Tet on/off system, has been incorporated into mouse genetics to achieve more precise conditional control of transgene expression (Santacruz et al., 2005). In recent studies, P301L mutant Tau was strictly expressed in Layer II/III neurons in the entorhinal cortex by neuropin promoter in combination with a tetracycline inducible system (de Calignon et al., 2012; Liu et al., 2012). An interesting finding was that this region-specific expression of tau causes progressive spreading of NFTs pathology along the tri-synaptic entorhinal-hippocampus circuit in an anterograde manner, suggesting the presence of toxic tau species that can be transmitted via trans-synaptic communication. This prion-like propagation theory is further supported by studies with in vivo administration of fibrillar tau aggregates into mouse brains resulting in the spread of tau pathology to synaptically connected distant brain regions (Clavaguera et al., 2009, 2013; Lasagna-Reeves et al., 2012; Iba et al., 2013). As an alternative approach, the AAV system has become a widely used technique to achieve spatiotemporal manipulation of transgene expression. In fact, circuit-dependent pathological spreading of tau pathology was also recently achieved by local administration of AAV-encoding mutant tau into the entorhinal cortex of adult rodent (Siman et al., 2013). Therefore, a very fascinating approach would be to generate a tau mouse model genetically modified in the local cell population of a specific neuronal circuit, and to trace the in vivo spatiotemporal consequence of tau propagation in the brain of the same individual living animal by fluorescence and PET simultaneously, which would potentially facilitate further understanding of non-cell autonomous toxic mechanisms shared among various neurodegenerative disorders.

Very recently, an artificial nuclease-mediated gene edition presented as the CRISPR/CAS9 system has rapidly expanded its utility for the generation of animal models from insects to a primate system (Sander and Joung, 2014). Using such innovative tools, the establishment of genetic imaging reporter animals is one of the attractive directions for future AD research. Several studies have demonstrated that herpes simplex virus type 1 thymidine kinase (HSV1-TK)-mediated phosphorylation and intracellular accumulation of nucleoside analogs such as 9-(4-fluoro-3-hydroxymethylbutyl) guanine (FHBG) is a useful PET reporter system for assessing gene expression, protein-protein interactions, and enzymatic activity (Gambhir et al., 2000; Luker et al., 2002; Massoud et al., 2010). Current advances in chemical biology are also creating the potential availability of multiple new technologies such as advanced affinity tag and light manipulation for various in vivo imaging applications (Kramer et al., 2013). Therefore, the combination of these genetic manipulations is certain to contribute to the efficient development of advanced animal model systems, and will allow us to conduct simultaneous multimodal imaging comparisons to monitor the sequential pathophysiology of AD progression.

CONCLUDING REMARKS

Multimodal neuroimaging may open an attractive direction for future translational research, and allow us to simultaneously monitor the actual behavior of target molecules of interest in living subjects from a microscopic to a macroscopic view. Based on the current progress of PET and the fluorescence system, there are still a lot of areas and issues to be addressed, and integration of these very different techniques will still present some challenging hurdles. At this moment, all we need is to sincerely evaluate both the advantages and disadvantages of individual imaging systems, and to consider ways to complement these very different techniques by seeking even small improvements in a step-by-step manner. Eventually, this steady work and effort will result in a breakthrough in the area of advanced biomedical research including future diagnostics.

AUTHOR CONTRIBUTIONS

Reseaching the data for the article: MS and NS. Drafting of the manuscript: MS. Discussion of the content: MS, MH, TS, and NS. Review and editing of the manuscript: MH, TS, and NS.

ACKNOWLEDGMENTS

Work in the authors’ laboratory is supported in part by Grants-in-Aid for Japan Advanced Molecular Imaging Program,
Scientific Research on Innovation Area (Brain Protein Aging, 26117001), Scientific Research (C) (15K06793) from the Ministry of Education, Culture, Sports, Science and Technology, Japan, and Brain Mapping by Integrated Neurotechnologies for Disease Studies (No. 14027042 and 14533254) from Japan Agency for Medical Research and development.

REFERENCES

Ariza, M., Kolb, H. C., Moechars, D., Rombouts, F., and Andrés, J. I. (2015). Tau positron emission tomography (PET) imaging: past, present, and future. J. Med. Chem. 58, 4365–4382. doi: 10.1021/jm501754J

Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., and Hyman, B. T. (1992). Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology 42, 631–639. doi: 10.1212/WNL.42.3.631

Bacskai, B. J., Hickey, G. A., Skoch, J., Kajdasz, S. T., Wang, Y., Huang, G. F., et al. (2003). Four-dimensional multimodal photon imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 100, 12462–12467. doi: 10.1073/pnas.203410100

Busche, M. A., Chen, X., Henning, H. A., Reichwald, J., Staufenbiel, M., Sakmann, B., et al. (2015). The fluorescent pentameric oligothiophene pFTAA identifies binding, and clearance of an amyloid-beta ligand in transgenic mouse. J. Nucl. Med. 58, 4365–4382. doi: 10.1021/jm501754J

Cowan, C. M., and Brain Mapping by Integrated Neurotechnologies for Disease Studies (No. 14027042 and 14533254) from Japan Agency for Medical Research and development.
Higuchi, M., Maeda, J., Ji, B., Maruyama, M., Okauchi, T., Tokunaga, M., et al. (2010). In-vivo visualization of key molecular processes involved in Alzheimer's disease pathogenesis: insights from neuroimaging research in humans and rodent models. Biochim. Biophys. Acta 1802, 373–388. doi: 10.1016/j.bbabal.2009.10.003

Hillman, E. M. (2007). Optical brain imaging in vivo: techniques and applications from animal to man. J. Biomed. Opt. 12, 051402. doi: 10.1117/1.2789693

Holmes, B. F., Furman, J. L., Mahan, T. E., Yamaski, T. R., Mirbaha, H., Eades, W. C., et al. (2014). Proteoplastic tau seed predicting tauopathy in vivo. Proc. Natl. Acad. Sci. U.S.A. 111, E4376–E4385. doi: 10.1073/pnas.1411649111

Huang, Y., and Mucke, L. (2012). Alzheimer mechanisms and therapeutic strategies. Cell 148, 1204–1222. doi: 10.1016/j.cell.2012.02.040

Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., et al. (1998). Association of missense and S’-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393, 702–705. doi: 10.1038/31508

Iba, M., Guo, J. L., McBride, J. D., Zhang, B., Trojanowski, J. Q., and Lee, V. M. (2013). Synthetic tau fibrils mediate transmission of neurofilibrillary tangles in a transgenic mouse model of Alzheimer’s-like tauopathy. J. Neurosci. 33, 1024–1037. doi: 10.1523/JNEUROSCI.2642-12.2013

Jack, C. R. Jr., and Holtzman, D. M. (2013). Biomarker modeling of Alzheimer’s disease. Neuron 80, 1347–1358. doi: 10.1016/j.neuron.2013.12.003

Jacobs, A. H., Tavitian, B., and INMIND consortium. (2012). Noninvasive molecular imaging of neuroinflammation. J. Cereb. Blood Flow Metab. 32, 1393–1415. doi: 10.1038/jcbfm.2012.53

Jameson, L. P., and Dzuba, S. V. (2013). Aza-BODIPY: improved synthesis and interaction with soluble Abeta1-42 oligomers. Biosorg. Med. Chem. Lett. 23, 1732–1735. doi: 10.1016/j.bmcl.2013.01.065

Ji, B., Maeda, J., Sawada, M., Ono, M., Okauchi, T., Inaji, M., et al. (2008). Imaging of peripheral benzodiazepine receptor expression as biomarkers of detrimental versus beneficial glial responses in mouse models of Alzheimer’s and other CNS pathologies. J. Neurosci. 28, 12255–12267. doi: 10.1523/JNEUROSCI.2312-08.2008

Klunk, W. E., Bacskaï, B. J., Mathis, C. A., Kajdasz, S. T., McLelland, M. E., Frosch, M. P., et al. (2004). Imaging brain amyloid in Alzheimer’s disease with Pittsburgh compound B reflects the amount of amyloid-β dense amyloid plaques in Alzheimer disease patients. J. Nucl. Med. 45, 531–561. doi: 10.2967/jnm.106.037556

Klunk, W. E., Lopresti, B. J., Ikonomovic, M. D., Lefterov, I. M., Koldamova, K., Kopeikina, K. J., Wegmann, S., Pitstick, R., Carlson, G. A., Bacskaï, B. J., Betensky, R. A., et al. (2013). Tau causes synapse loss without disrupting calcium homeostasis in vivo. Proc. Natl. Acad. Sci. U.S.A. 110, 816–823. doi: 10.1073/pnas.1310670110

Klunk, W. E., Bacskai, B. J., Mathis, C. A., Kajdasz, S. T., McLelland, M. E., Frosch, M. P., et al. (2014). Amyloid PET imaging in Alzheimer’s disease: a comparison of three radiotracers. Eur. J. Nucl. Med. Mol. Imaging 41, 1398–1407. doi: 10.1007/s00259-014-2753-3

Koeppel, F. T., Paulmuran, R., and Gambhir, S. S. (2010). A molecularly engineered split reporter for imaging protein-protein interactions with positron emission tomography. Nat. Med. 16, 921–926. doi: 10.1038/nm.2185

Koch, J. M., Breault, C., and Bishop, J. W. (2013). Amyloid-beta imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J. Nucl. Med. 54, 70–77. doi: 10.2967/jnm.112.190909

Lancaster, C. T., Thomas, B. A., Thiruvali, E., Schmidt, M., Margolin, R., Mintun, M., et al. (2014). Amyloid PET imaging in Alzheimer’s disease: a comparison of three radiotracers. Eur. J. Nucl. Med. Mol. Imaging 41, 1398–1407. doi: 10.1007/s00259-014-2753-3

Levi, V. M., Goedert, M., and Trojanowski, J. Q. (2001). Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24, 1121–1139. doi: 10.1146/annurev.neuro.24.1.1121

Li, L., Drouet, V., Wu, J. W., Witter, M. P., Small, S. A., Clelland, C., et al. (2012). Trans-synaptic spread of tau pathology in vivo. PLoS ONE 7:e31302. doi: 10.1371/journal.pone.0031302

Luker, G. D., Sharma, V., Pica, C. M., Dahlheimer, J. L., Li, W., Ochesky, J., et al. (2002). Noninvasive imaging of protein-protein interactions in living animals. Proc. Natl. Acad. Sci. U.S.A. 99, 6961–6966. doi: 10.1073/pnas.0922239

Maeda, J., Higuchi, M., Inaji, M., Ji, B., Haneda, E., Okauchi, T., et al. (2007). Phase-dependent roles of reactive microglia and astrocytes in nervous system injury as delineated by imaging of peripheral benzodiazepine receptor. Brain Res. 1157, 100–111. doi: 10.1016/j.brainres.2007.04.054

Maruyama, M., Shimada, H., Suhara, T., Shinotoh, H., Ji, B., Maeda, J., et al. (2007). Increased levels of granular tau oligomers: an early sign of brain aging and Alzheimer’s disease. Neurosci. Res. 54, 197–201. doi: 10.1016/j.neures.2005.11.009

Makrides, V., Shen, T. E., Bhatia, R., Smith, B. L., Thimm, J., Lal, R., et al. (2003). Microtubule-dependent oligomerization of tau. Implications for physiological tau function and tauopathies. J. Biol. Chem. 278, 33298–33304. doi: 10.1074/jbc.M30527020

Marcus, J. N., and Schachter, J. (2011). Targeting post-translational modifications on tau as a therapeutic strategy for Alzheimer’s disease. J. Neurogenet. 25, 127–133. doi: 10.3109/01677063.2011.626671

Marquie, M., Normandin, M. D., Vanderburg, C. R., Costantino, I. M., Bien, E. A., Rycyna, L. G., et al. (2015). Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann. Neurol. 78, 787–800. doi: 10.1002/ana.24517

Mishima, H., Suhara, T., Shinotoh, H., Ji, B., Maeda, J., et al. (2013). Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuropharmacology 78, 1094–1108. doi: 10.1016/j.neuropharm.2013.07.037

Mishima, H., Suhara, T., Shinotoh, H., Ji, B., Maeda, J., et al. (2013). Tau causes synapse loss without disrupting calcium homeostasis in the rTg4510 model of tauopathy. PLoS ONE 8:e80834. doi: 10.1371/journal.pone.0080834

Kramer, R. H., Mourot, A., and Adesnik, H. (2013). Optogenetic pharmacology for control of native neuronal signaling proteins. Nat. Neurosci. 16, 816–823. doi: 10.1038/nmn.2013.3424
Shimojo et al.

In vivo Imaging of AD

Meyer-Luehmann, M., Spires-Jones, T. L., Prada, C., Garcia-Alloza, M., de Calignon, A., Rozkalne, A., et al. (2008). Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature 451, 729–724. doi: 10.1038/nature06616

Miyawaki, A., and Nishiyama, Y. (2015). Molecular spies for bioimaging—fluorescent protein-based probes. Mol. Cell 58, 632–643. doi: 10.1016/j.molcel.2015.03.002

Mori, T., Maeda, J., Shimada, H., Higuchi, M., Shinohara, U., Ueno, S., et al. (2012). Molecular imaging of dementia. Psychogeriatrics 12, 106–114. doi: 10.1111/j.1479-8301.2012.00409.x

Mosconi, L. (2005). Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur. J. Nucl. Med. Mol. Imaging 32, 486–510. doi: 10.1007/s00259-005-1762-7

Oh, G., Chung, E., and Yun, S. H. (2013). Optical fibers for high-resolution in vivo microendoscopic fluorescence imaging. Opt. Fiber Technol. 19, 760–771. doi: 10.1016/j.yofte.2013.07.008

Okamura, N., Furumoto, S., Harada, R., Tago, T., Iwata, R., Tashiro, M., et al. (2014). Characterization of [18F]THK-3531, a novel PET tracer for imaging tau pathology in Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 41, S260–S260.

Patterson, K. R., Remmers, C., Fu, Y., Brooker, S., Kanaan, N. M., Vana, L., et al. (2013). Alzheimer’s disease: genes, proteins, and therapy. Lancet Neurol. 12, 1062–1071. doi: 10.1016/S1474-4422(13)70315-0

Peterson, D. W., Zhou, H., Dahlquist, F. W., and Lew, J. (2008). A soluble oligomer of tau associated with fiber formation analyzed by NMR. Biochemistry 47, 7393–7404. doi: 10.1021/bi702466a

Piel, M., Vernaleken, I., and Rösch, F. (2014). Positron emission tomography in the brains of living patients with Alzheimer disease. Am. J. Geriatr. Psychiatry 10, 24–35. doi: 10.1097/JG.0b013e318291a4ef

Siman, R., Lin, Y. G., Malthankar-Phatak, G., and Dong, Y. (2013). A rapid gene delivery-based mouse model for early-stage Alzheimer disease-type tauopathy. J. Neuropathol. Exp. Neurol. 72, 1062–1071. doi: 10.1097/NEN.0b013e318261802d

Small, G. W., Kepe, V., Ercoli, L. M., Siddarth, P., Bookheimer, S. Y., Miller, K. J., et al. (2006). PET of brain amyloid and tau in mild cognitive impairment. N. Engl. J. Med. 355, 2652–2663. doi: 10.1056/NEJMoa054625

Smid, L. M., Kepe, V., Vinters, H. V., Bresnajac, M., Toyokuni, T., Satymurthy, N., et al. (2013). Postmortem 3-D brain hemisphere cortical tau and amyloid-beta pathology mapping and quantification as a validation method of neuropathology imaging. J. Alzheimers. Dis. 36, 261–274. doi: 10.3233/JAD-122434

Smith, N. W., Alonso, A., Brown, C. M., and Drysba, S. V. (2010). Triazole-containing BODIPY dyes as novel fluorescent probes for soluble oligomers of amyloid β-peptide. Biochem. Biophys. Res. Commun. 391, 1455–1458. doi: 10.1016/j.bbrc.2009.12.091

Spillantini, M. G., Murrell, J. R., Goedert, M., Farlow, M. R., Klug, A., and Gheiti, B. (1998). Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc. Natl. Acad. Sci. U.S.A. 95, 7737–7741. doi: 10.1073/pnas.95.13.7737

Spires, T. L., Meyer-Luehmann, M., Stern, E. A., McLean, P. J., Skoch, J., Nguyen, P. T., et al. (2005). Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J. Neurosci. 25, 7278–7287. doi: 10.1523/JNEUROSCI.1879-05.2005

Spires-Jones, T. L., de Calignon, A., Matsu, T., Zehr, C., Pitstick, R., Wu, H. Y., et al. (2008). In vivo imaging reveals dissociation between caspase activation and acute neuronal death in tangle-bearing neurons. J. Neurosci. 28, 862–867. doi: 10.1523/JNEUROSCI.3072-08.2008

Spires-Jones, T. L., Koepinka, K. J., Koffie, R. M., de Calignon, A., and Hyman, B. T. (2011). Are tangles as toxic as they look? J. Mol. Neurosci. 45, 438–444. doi: 10.1007/s12031-011-9566-7

Svoboda, K., and Yasuda, R. (2006). Principles of two-photon excitation microscopy and its applications to neuroscience. Neuron 50, 823–839. doi: 10.1016/j.neuron.2005.05.019

Tago, T., Furumoto, S., Okamura, N., Harada, R., Ishikawa, Y., Arai, H., et al. (2014). Synthesis and preliminary evaluation of 2-arylhydroxquinoline derivatives for tau imaging. J. Labelled Comp. Radiopharm. 57, 18–24. doi: 10.1002/jlcr.3133

Takano, T., Han, X., Deane, R., Zilovic, B., and Niedergered, M. (2007). Two-photon imaging of astrocytic Ca2+ signaling and the microvasculature in experimental mice models of Alzheimer's disease. Ann. N.Y. Acad. Sci. 1097, 40–50. doi: 10.1196/annals.1379.004

Teoh, C. L., Su, D., Sahu, S., Yun, S. W., Drummond, E., Prelli, F., et al. (2015). Chemical fluorescent probe for detection of abeta oligomers. J. Am. Chem. Soc. 137, 13503–13509. doi: 10.1021/jacs.5b06190

Thompson, P. W., Ye, L., Morgenstern, J. L., Sue, L., Beach, T. G., Judd, D. J., et al. (2009). Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer's disease pathologies. J. Neurochem. 109, 623–630. doi: 10.1111/j.1471-4159.2009.05996.x

Tomita, Y., Kubis, N., Calandro, Y., Tran Dinh, A., Mercier, P., Seylaz, J., et al. (2005). Long-term in vivo investigation of mouse cerebral microcirculation by fluorescence confocal microscopy in the area of focal ischemia. J. Cereb. Blood Flow Metab. 25, 858–867. doi: 10.1093/jcbfm/960077

Turkheimer, F. E., Rizzo, G., Bloomfield, P. S., Howes, O., Zanotti-Fregonara, P., Bertoldo, A., et al. (2015). The methodology of TSPO imaging with positron emission tomography. Biochem. Soc. Trans. 43, 586–592. doi: 10.1042/BST20150058

Vallabhapurolu, S. (2011). Positron emission tomography radiopharmaceuticals for imaging brain Beta-amyloid. Semin. Nucl. Med. 41, 283–299. doi: 10.1053/j.snumed.2011.02.005

Vandenbergh, R., Van Laere, K., Ivanou, A., Salman, E., Bastin, C., Triau, E., et al. (2010). 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann. Neurol. 68, 319–329. doi: 10.1002/ana.22068

Shimojo et al.
Venneti, S., Lopresti, B. J., and Wiley, C. A. (2006). The peripheral benzodiazepine receptor (Translocator protein 18kDa) in microglia: from pathology to imaging. *Prog. Neurobiol.* 80, 308–322. doi: 10.1016/j.pneurobio.2006.10.002

Venneti, S., Lopresti, B. J., and Wiley, C. A. (2013). Molecular imaging of microglia/macrophages in the brain. *Glia* 61, 10–23. doi: 10.1002/glia.22357

Villemagne, V. L., Fodero-Tavoletti, M. T., Masters, C. L., and Rowe, C. C. (2015). Tau imaging: early progress and future directions. *Lancet Neurol.* 14, 114–124. doi: 10.1016/S1474-4422(14)70252-2

Villemagne, V. L., Furumoto, S., Fodero-Tavoletti, M. T., Mulligan, R. S., Hodges, J., Harada, R., et al. (2014). In vivo evaluation of a novel tau imaging tracer for Alzheimer’s disease. *Eur. J. Nucl. Med. Mol. Imaging* 41, 816–826. doi: 10.1007/s00259-013-2681-7

Wilt, B. A., Burns, L. D., Wei Ho, E. T., Ghosh, K. K., Mukamel, E. A., and Schnitzer, M. J. (2009). Advances in light microscopy for neuroscience. *Annu. Rev. Neurosci.* 32, 435–506. doi: 10.1146/annurev.neuro.051508.135540

Wischik, C. M., Edwards, P. C., Lai, R. Y., Roth, M., and Harrington, C. R. (1996). Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. *Proc. Natl. Acad. Sci. U.S.A.* 93, 11213–11218. doi: 10.1073/pnas.93.20.11213

Wolk, D. A., Zhang, Z., Boudhar, S., Clark, C. M., Pontecorvo, M. J., and Arnold, S. E. (2012). Amyloid imaging in Alzheimer’s disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography. *J. Neurol. Neurosurg. Psychiatr.* 83, 923–926. doi: 10.1136/jnnp-2012-302548

Xia, C. F., Arteaga, J., Chen, G., Gangadharmath, U., Gomez, L. F., Kasi, D., et al. (2013). [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer’s disease. *Alzheimers. Dement.* 9, 666–676. doi: 10.1016/j.jalz.2012.11.008

Yang, L., Rieves, D., and Ganley, C. (2012). Brain amyloid imaging—FDA approval of florbetapir F18 injection. *N. Engl. J. Med.* 367, 885–887. doi: 10.1056/NEJMmp1208061

Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S. M., Iwata, N., Saito, T. C., et al. (2007). Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. *Neuron* 53, 337–351. doi: 10.1016/j.neuron.2007.01.010

Yousefi, B. H., Drzezga, A., Von Reutern, B., Manook, A., Schweiger, M., Wester, H. J., et al. (2011). A novel (18)F-labeled Imidazo[2,1-b]benzothiazole (IBT) for high-contrast PET imaging of beta-amyloid plaques. *ACS Med. Chem. Lett.* 2, 673–677. doi: 10.1021/ml200123w

Zhang, W., Arteaga, J., Cashion, D. K., Chen, G., Gangadharmath, U., Gomez, L. F., et al. (2012). A highly selective and specific PET tracer for imaging of tau pathologies. *J. Alzheimers Dis.* 31, 601–612. doi: 10.3233/JAD-2012-120712

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Copyright © 2015 Shimojo, Higuchi, Sahara and Sahara. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*